Lung cancer drug combo trial pulled before it began
NCT ID NCT05472623
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study planned to test a targeted cancer pill (adagrasib) alone or with an immunotherapy drug (nivolumab) before surgery in people with a specific type of lung cancer (KRAS G12C mutation). The goal was to see if these drugs could eliminate all cancer cells by the time of surgery. However, the trial was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adagrasib (a targeted cancer pill) with or without nivolumab (an immunotherapy drug)
What this could lead to
If successful, this approach could shrink lung tumors before surgery, potentially improving outcomes for people with KRAS G12C mutations.
What could go wrong
The trial was withdrawn before enrolling any participants, so no data is available. It is unclear if the combination would be safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins
Baltimore, Maryland, 21231, United States